Research Programs

The CombinatoRx preclinical pipeline includes multiple drug candidates targeted for potential development in multiple immuno-inflammatory diseases, oncology, neurodegenerative diseases, infectious diseases and other therapeutic areas. CombinatoRx is now advancing first prospects into later-stage clinical trials, while our early-stage clinical programs and preclinical and discovery projects continue to progress.

Neurodegenerative Disease

Collaborations with Cure Huntington's Disease Initiative (CHDI), Spinal Muscular Atrophy Foundation (SMAF), and National Institutes of Health (NIH).

Medical Devices

Collaboration with Angiotech to discover and develop compounds for use in medical devices and other interventional medicine products.

Ophthalmic Disease

Collaboration with Fovea Pharmaceuticals SA to develop novel treatments for ophthalmic diseases.

Infectious Disease

Screening combinations through our subsidiary, CombinatoRx Singapore, and in collaboration with Bio*One Singapore.

Cystic Fibrosis

Collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT).

Biodefense

Potential therapeutics for anthrax toxin through grant from National Institute of Allergy and Infectious Disease (NIAID).